Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
Abstract Treatment options for patients with brain metastases (BMs) have limited efficacy
and the mortality rate is virtually 100%. Targeted therapy is critically under‐utilized, and our …
and the mortality rate is virtually 100%. Targeted therapy is critically under‐utilized, and our …
[引用][C] Integrated genomic and transcriptomic analysis of human brain metastases identifies recurrently altered pathways of potential clinical significance
JM Saunus, MICJ Quinn, AM Patch… - Journal of …, 2015 - espace.library.uq.edu.au
Treatment options for patients with brain metastases (BMs) have limited efficacy and the
mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our …
mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our …
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
JM Saunus, MC Quinn, AM Patch… - The Journal of …, 2015 - europepmc.org
Treatment options for patients with brain metastases (BMs) have limited efficacy and the
mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our …
mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our …
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
JM Saunus, MCJ Quinn, AM Patch… - Journal of …, 2015 - research.monash.edu
Abstract Treatment options for patients with brain metastases (BMs) have limited efficacy
and the mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our …
and the mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our …
[引用][C] Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
J Saunus, M Quinn, A Patch, J Pearson, P Bailey… - 2015 - hekyll.services.adelaide.edu.au
Adelaide Research & Scholarship: Integrated genomic and transcriptomic analysis of human
brain metastases identifies alterations of potential clinical significance Skip navigation DSpace …
brain metastases identifies alterations of potential clinical significance Skip navigation DSpace …
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
JM Saunus, MCJ Quinn, AM Patch, JV Pearson… - The Journal of …, 2015 - infona.pl
Treatment options for patients with brain metastases (BMs) have limited efficacy and the
mortality rate is virtually 100%. Targeted therapy is critically under‐utilized, and our …
mortality rate is virtually 100%. Targeted therapy is critically under‐utilized, and our …
[引用][C] Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
J Saunus, M Quinn, A Patch, J Pearson, P Bailey… - 2015 - digital.library.adelaide.edu.au
Adelaide Research & Scholarship: Integrated genomic and transcriptomic analysis of human
brain metastases identifies alterations of potential clinical significance Skip navigation DSpace …
brain metastases identifies alterations of potential clinical significance Skip navigation DSpace …
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
JM Saunus, MC Quinn, AM Patch, JV Pearson… - Journal of …, 2015 - hero.epa.gov
Abstract Treatment options for patients with brain metastases (BMs) have limited efficacy
and the mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our …
and the mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our …
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
JM Saunus, MCJ Quinn, AM Patch, JV Pearson… - Journal of …, 2015 - eprints.gla.ac.uk
Treatment options for patients with brain metastases (BMs) have limited efficacy and the
mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our …
mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our …
Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance
JM Saunus, MCJ Quinn, AM Patch… - The Journal of …, 2015 - pubmed.ncbi.nlm.nih.gov
Treatment options for patients with brain metastases (BMs) have limited efficacy and the
mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our …
mortality rate is virtually 100%. Targeted therapy is critically under-utilized, and our …